Patent Grant
8586617
This application claims the benefit of European Patent Application No. 06122586.8, filed Oct. 19, 2006, which is hereby incorporated by reference in its entirety.
This application relates to compounds which have a good affinity to the trace amino associated receptors (TAARs), especially for TAAR1.
The invention relates also to processes for preparing such compounds, a pharmaceutical composition comprising such a compound, and a method for treating a disease or disorder in a patient comprising administering such a compound to a patient in need of such treatment.
It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.
The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
The classical biogenic amines (serotonin, norepinephrine, epinephrine, dopamine, histamine) play important roles as neurotransmitters in the central and peripheral nervous system. Deutch, A. Y. and Roth, R. H. (1999) Neurotransmitters. In Fundamental Neuroscience (2nd edn) (Zigmond, M. J., Bloom, F. E., Landis, S. C., Roberts, J. L., and Squire, L. R., eds.), pp. 193-234, Academic Press. Their synthesis and storage, as well as their degradation and reuptake after release are tightly regulated. An imbalance in the levels of biogenic amines is known to be responsible for the altered brain function under many pathological conditions. Wong, M. L. and J. Licinio (2001)Nat. Rev. Neurosci., 2, 343-351; Carlsson, A. et al. (2001) Annu. Rev. Pharmacol. Toxicol, 41, 237-260; Tuite, P., and J. Riss (2003) Expert Opin. Invest. Drugs, 12, 1335-1352; Castellanos, F. X. and R. Tannock (2002) Nat. Rev. Neurosci., 3, 617-628.
A second class of endogenous amine compounds, the so-called trace amines (TAs) significantly overlap with the classical biogenic amines regarding structure, metabolism and subcellular localization. The TAs include p-tyramine, β-phenylethylamine, tryptamine and octopamine, and they are present in the mammalian nervous system at generally lower levels than classical biogenic amines. Ursdin, Earl; Sandler, Merton; Editors. Psychopharmacology Series, Vol. 1: Trace Amines and the Brain [Proceedings of a Study Group at the 14th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico] (1976). Their disregulation has been linked to various psychiatric diseases like schizophrenia and depression and for other conditions like attention deficit hyperactivity disorder, migraine headache, Parkinson's disease, substance abuse and eating disorders Lindemann, L. and M. Hoener (2005) Trends in Phamacol. Sci. 26, 274-281; Branchek, T. A. and T. P. Blackburn (2003) Curr. Opin. Pharmacol., 3, 90-97; Premont, R. T. et al. (2001) Proc. Natl. Acad. Sci. S. A. 98, 9474-9475.
For a long time, TA-specific receptors had only been hypothesized based on anatomically discrete high-affinity TA binding sites in the central nervous system of humans and other mammals. Mousseau, D. D. and R. F. Butterworth (1995) Prog. Brain Res. 106, 285-291; McCormack, J. K. et al. (1986) J. Neurosci. 6, 94-101. Accordingly, the pharmacological effects of TAs were believed to be mediated through the well known machinery of classical biogenic amines, by either triggering their release, inhibiting their reuptake or by “cross reacting” with their receptor systems. Premont, R. T. et al. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 9474-9475; Dyck, L. F. (1989) Life Sci. 44, 1149-1156; Paker, E. M. and L. X. Cubeddu (1988) J. Pharmacol. Exp. Ther. 245, 199-210. This view changed significantly with the recent identification of several members of a novel family of GPCRs, the trace amine associated receptors (TAARs). Lindemann, L. and M. Hoener (2005) Trends in Pharmacol. Sci, 26, 274-281; Lindemann, L. et al. (2005) Genomics, 85, 372-385. There are 9 TAAR genes in human (including 3 pseudogenes) and 16 genes in mouse (including 1 pseudogene). The TAAR genes do not contain introns (with one exception, TAAR2 contains 1 intron) and are located next to each other on the same chromosomal segment. The phylogenetic relationship of the receptor genes, in agreement with an in-depth GPCR pharmacophore similarity comparison and pharmacological data suggest that these receptors form three distinct subfamilies Lindemann, L. and M. Hoener (2005) Trends in Pharmacol. Sci. 26, 274-281; Lindemann, L. et al. (2005), Genomics, 85, 372-385. TAAR1 is in the first subclass of four genes (TAAR1-4) highly conserved between human and rodents. TAs activate TAAR1 via Gαs. Dysregulation of TAs was shown to contribute to the aetiology of various diseases like depression, psychosis, attention deficit hyperactivity disorder, substance abuse, Parkinson's disease, migraine headache, eating disorders, metabolic disorders and therefore TAAR1 ligands have a high potential for the treatment of these diseases.
The present invention relates to compounds which have a good affinity to the trace amino associated receptors (TAARs), especially for TAAR1.
The present invention relates to a compound of formula I
wherein:
A further aspect of the present invention are processes for the preparation of the above compound.
Yet another aspect of the present invention is a pharmaceutical composition comprising the above compound or pharmaceutically-acceptable salt thereof.
Yet another aspect of the present invention is a method for treating a disease or disorder in a patient comprising administering the above compound, or pharmaceutically-acceptable salt thereof, to a patient in need of such treatment.
The present invention relates to a compound of formula I
wherein:
Furthermore, the invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers. In addition, all tautomeric forms of compounds of formula I are also encompassed by the present invention.
Such compounds have a good affinity to the trace amino associated receptors (TAARs), especially for TAAR1 and may be used in the control or prevention of illnesses such as depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
In preferred embodiments, the compounds of the present invention, or their pharmaceuticaly-accpetable salts, are used for treating depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD).
As used herein, the term “lower alkyl” denotes a saturated straight- or branched-chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are groups with 1-4 carbon atoms.
As used herein, the term “lower alkoxy” denotes a substituent in which an alkyl group is attached via an oxygen atom to the remainder of the molecule.
As used herein, the term “cycloalkyl” denotes a saturated carbon ring containing 3 to 7 carbon atoms, for example cyclopropyl, cyclohexyl and the like.
As used herein, the term “lower alkyl substituted by halogen” denotes a saturated straight- or branched-chain group containing from 1 to 7 carbon atoms wherein one or more hydrogen atoms are replaced by a halogen atom, for example —CH2F, —CF3,
As used herein, the term “lower alkyl substituted by halogen” denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example —CF3, —CHF2, —CH2F, —CH2CF3, —CF2CHF2, —CF2CF3, —CH2CH2CF3, —CH2CF2CF3 and the like.
As used herein, the term “lower alkoxy substituted by halogen” denotes a lower alkoxy group as defined above wherein one or more hydrogen atoms are replaced by a halogen atom, for example —OCH2F, —OCF3, —OCF2CF3, —OCH2CH2CF3, and —OCH2CF2CF3.
As used herein, the term “lower alkyl substituted by halogen” denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example —CF3, —CHF2, —CH2F, —OCH2CF3, —OCF2CHF2 and the like.
As used herein, the term “aryl” denotes a carbon ring or ring system, wherein at least one ring is aromatic in nature, for example phenyl, naphthyl, or indanyl.
As used herein, the term “heteroaryl” denotes an aromatic ring or a ring system selected from the group consisting of quinolinyl, pyrazinyl, thiophenyl, pyrrolyl, imidazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, benzofuranyl, benzo[1.3]dioxolyl and indolyl.
As used herein, the term “heterocyclyl” denotes a non-aromatic ring group selected from the group consisting of morpholinyl, pyrrolidinyl, [1.3]dioxalanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, and oxetanyl.
The term “halogen” denotes chlorine, iodine, fluorine or bromine.
The term “thiophenyl” denotes an aromatic ring containing 5 members of which 4 are carbon atoms and one is a sulfur atom.
The term “pharmaceutically acceptable salts” embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
In an embodiment of the present invention, the compound is a compound of formula IA
wherein:
Preferred compounds of the present invention are those of formula I wherein R1 is lower alkyl.
Especially preferred from this group are those wherein R2 is optionally substituted aryl, for example the following compounds:
Also preferred are compounds of formula I wherein R1 is hydrogen. Especially preferred from this group are such compounds wherein R2 is optionally substituted aryl, for example the following compounds:
Also preferred are compounds of formula I wherein R1 is lower alkyl and R2 is optionally substituted heteroaryl, for example the following compounds:
A further embodiment of the invention are compounds of formula I wherein R1 is optionally substituted CH2-aryl. Especially preferred from this group are such compounds wherein R2 is optionally substituted aryl, for example the following compounds:
Also preferred are compounds of formula I wherein R1 is CRH-cycloalkyl and R2 is optionally substituted aryl, for example:
The present compounds of formula I and their pharmaceutically-acceptable salts can be prepared by methods known in the art, for example, by processes described below.
One such process comprises reacting an amine of formula II
with a compound of formula III
to produce a compound of formula I
wherein R1, R2, R3, and R4 are as defined above.
Another such process comprises reacting a compound of formula I-1
with a compound of formula R1′—CHO
to produce a compound of formula I-2
wherein R1′ is selected from the group consisting of:
lower alkyl;
The other variables are as described above.
Yet another such process comprises reacting a compound of formula I-1
with a compound of formula V
to produce a compound of formula I-3
wherein the substituents are as defined above.
Yet another such process comprises removing a protecting group (denoted as “PG” below) from a compound of formula VI or a compound of formula X
to produce a compound of formula I
wherein the substituents are as defined above, wherein the preferred protecting group is 2-trimethylsilanyl-ethoxymethyl.
If desired, the compound obtained by one of the processes described above may be converted into a pharmaceutically-acceptable salt.
The following are general schemes which exemplify the use of the above processes in the production of compounds of formula I. The starting materials are either commercially available, (e.g. from one or more of the following chemical suppliers such as Aldrich, Fluka, Acros, Maybridge, Avocado, TCI, or additional suppliers as indicated in databases such as Chemical Abstracts [American Chemical Society, Columbus, Ohio] or Available Chemicals Directory [Elsevier MDL, San Ramon, Calif.])”, are otherwise known in the chemical literature, or may be prepared in accordance with methods described in the specific examples.
Method 1
Compounds of formula I may be prepared by reductive amination using an amine of formula II and a corresponding imidazole-4-carbaldehyde/ketone of formula III.
Method 2
Compounds of formula I-1 may be prepared by reductive amination followed by N-derivatisation to obtain compounds of formulas I-2 or 1-3.
The other variables are as described above.
Method 3
Compounds of formula I may be prepared from protected compounds of formula VI by removal of the protecting group (“PG”). The protecting groups are known groups described in the literature. The preferred protecting group is 2-trimethylsilanyl-ethoxymethyl.
Method 4
The processes described in scheme 4 are preferred for compounds wherein R2 is substituted or unsubstituted pyridine-4-yl, pyridine-2-yl, pyrimidin-4-yl or pyrimidine-2-yl. The corresponding heteroaryl compounds of formula I-4 may then be prepared by reaction of halogen substituted compounds of formula IX (Y═F preferred for pyridinyl; Y═Cl or Br preferred for pyrimidinyl) with protected aminomethylimidazoles of formula VIII to afford protected compounds of formula X followed by deprotection to afford compounds of formula I-4. Optionally the substituent R2 in compound X (if R2 is for instance a bromo- or chlorosubstituted pyridine or pyrimidine) can be transformed into a different substituent R2, (for instance an unsubstituted or alkoxysubstituted pyridine or pyrimidine) before deprotection by a suitable reaction such as hydrogenation or nucleophilic substitution (replacement of the bromo- or chlorosubstituent in R2 by hydrogen or alkoxy). “PG” refers to a protecting group and the variables are as described previously. The preferred protecting group is 2-trimethylsilanyl-ethoxymethyl.
Isolation and Purification of the Compounds
Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral compounds of formula I can be separated using chiral HPLC.
Salts of Compounds of Formula I
The compounds of formula I are basic and may be converted to a corresponding acid addition salt. The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0° C. and 50° C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.
The acid addition salts of the basic compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
The compounds of formula I and their pharmaceutically-acceptable salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention have a good affinity to the trace amine associated receptors (TAARs), especially TAAR1.
Pharmaceutical compositions containing a compound of formula I or a pharmaceutically-acceptable salt thereof and a therapeutically-inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically-acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically-inert carriers.
The pharmaceutical compositions can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, and parenterally, e.g. in the form of injection solutions.
The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical compositions. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
The pharmaceutical compositions can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
The present invention relates also to a method for treating a disease or disorder in a patient comprising administering a therapeutically-effective amount of a compound of the present invention to a patient in need of such treatment. A “therapeutically-effective amount” is the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. The above method may involve the administration of a composition which comprises a therapeutically-effective amount of the compound such as the compositions described above.
In preferred embodiments, the compound is used to treat disorders of the central nervous system, for example the treatment or prevention of schizophrenia, depression, cognitive impairment and Alzheimer's disease.
The therapeutically-effective amount can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
Manufacturing Procedure
Manufacturing Procedure
The following examples illustrate the invention but are not intended to limit its scope.
To a solution of N-ethylaniline (0.145 g, 1.2 mmol) in 1,2-dichloroethane (5 ml) were added molecular sieves (2 g, size 0.4 nM) and 4-formylimidazole (0.3 g, 3.12 mmol). After stirring the mixture for 5 min at room temperature sodium triacetoxyborohydride (1.02 g, 4.8 mmol) and acetic acid (5 drops) were added. The reaction mixture was stirred at room temperature overnight. For workup ethyl acetate (50 ml) and 1 M sodium bicarbonate solution (30 ml) were added and the mixture was shaken. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: ethyl acetate/methanol=95:5) to yield a white solid (122 mg, 51%); MS (ISP): 202.0 ((M+H)+.).
The title compound, MS (ISP): 188.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using N-methylaniline instead of N-ethylaniline.
To a saturated solution of ethylamine in methanol (40 ml) was added 4-formyl-imidazole-1-sulfonic acid dimethylamide (2.5 g, 12.3 mmol) and the mixture was stirred overnight. Sodium borohydride (0.70 g, 18.5 mmol) was added and the mixture was stirred at room temperature for 3 h. Water was added and the solution was extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and evaporated. The residue was purified by flash chromatography (SiO2: dichloromethane/methanol=9:1) to yield a light yellow oil (0.785 g, 27%); MS (ISP): 233.1 ((M+H)+.).
A mixture of 5-ethylaminomethyl-imidazole-1-sulfonic acid dimethylamide (0.2 g, 0.86 mmol) and 2-chloro-4-fluoropyridine (0.12 g; 0.91 mmol) was heated in a sealed vessel in a microwave oven for 30 min at 140° C. Then after cooling a solution of hydrochloric acid in ethanol (5 N, 1 ml) was added and the mixture was stirred at 90° C. overnight. For workup aqueous ammonia solution was added to basic pH and the mixture was extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and evaporated. The residue was purified by flash chromatography (SiO2; ethyl acetate/methanol 8:2) to yield a white solid, (0.13 g, 64%); MS (ISP): 239.0 ((M+H)+.).
The title compound, MS (EI): 205.1 (M+.) was obtained in comparable yield analogous to the procedure described for Example 1 using N-methyl-3-fluoroaniline instead of N-ethylaniline.
The title compound, MS (ISP): 202.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using N-methyl-o-tolylamine instead of N-ethylaniline.
The title compound, MS (ISP): 216.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using N-ethyl-m-tolylamine instead of N-ethylaniline.
The title compound, MS (ISP): 216.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using isoporopyl-phenyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 221.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 2-(chlorophenyl)-methyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 221.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 3-(chlorophenyl)-methyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 221.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 4-(chlorophenyl)-methyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 256.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using cyclohexyl-phenyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 218.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 2-phenylamino-ethanol instead of N-ethylaniline.
The title compound, MS (ISP): 218.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (2-methoxy-phenyl)-methyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 236.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 3-(chlorophenyl)-methyl-amine instead of N-ethylaniline and 4-formyl-2-methylimidazole instead of 4-formylimidazole.
The title compound, MS (ISP): 235.8 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 3-(chlorophenyl)-methyl-amine instead of N-ethylaniline and 4-formyl-5-methylimidazole instead of 4-formylimidazole.
The title compound, MS (ISP): 366.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-chloro-phenyl)-(3-trifluoromethyl-benzyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 327.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-chloro-phenyl)-(3-methoxy-benzyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 332.0; 334.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (2-chloro-benzyl)-(3-chloro-phenyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 331.9; 334.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-chloro-benzyl)-(3-chloro-phenyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 332.0; 334.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (4-chloro-benzyl)-(3-chloro-phenyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 298.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using benzyl-(3-chloro-phenyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 341.9; 343.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-bromo-benzyl)-phenyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 250.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-chloro-phenyl)-isopropyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 283.9; 285.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3,5-dichloro-phenyl)-isopropyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 246.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using isopropyl-(3-methoxy-phenyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 230.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using N-isopropyl-m-tolylamine instead of N-ethylaniline.
The title compound, MS (ISP): 284.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using N-isopropyl-3-(trifluoromethyl)aniline instead of N-ethylaniline.
The title compound, MS (ISP): 250.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (4-chloro-phenyl)-isopropyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 246.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using isopropyl-(4-methoxy-phenyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 250.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using diphenyl-amine instead of N-ethylaniline.
5-Amino-2-chlorobenzotrifluoride (0.587 g, 3.0 mmol) was dissolved in methanol (30 ml). Then acetone (1.58 ml, 30 mmol) and zinc chloride (1.635 g, 12 mmol) were added and the reaction mixture was cooled with an ice bath. After adding sodium cyanoborohydride (0.566 g, 9.0 mmol) the mixture was allowed to stir at 40° C. overnight. After cooling, the reaction mixture was poured onto ammonium chloride/ice and extracted with ethyl acetate (2 times 50 ml). The organic layer was dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (SiO2; eluent: heptane/ethyl acetate=95:5) to yield a light yellow oil (0.530 g, 74%) that was directly used for the next step; MS (EI): 222.1 ((M-CH3)+); 237.1 (M+.).
(4-Chloro-3-trifluoromethyl-phenyl)-(3H-imidazol-4-ylmethyl)-isopropyl-amine, MS (ISP): 318.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (4-chloro-3-trifluoromethyl-phenyl)-isopropyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 284.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3,4-dichloro-phenyl)-isopropyl-amine instead of N-ethylaniline.
(3-Chloro-4-trifluoromethoxy-phenyl)-isopropyl-amine was obtained in comparable yield analogous to the procedure described for Example 31 step a) using 3-chloro-4-trifluoromethoxy-phenylamine instead of 5-amino-2-chlorobenzotrifluoride and was used directly in the next step.
The title compound, MS (ISP): 334.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-chloro-4-trifluoromethoxy-phenyl)-isopropyl-amine instead of N-ethylaniline.
Isopropyl-(3-methoxy-5-trifluoromethyl-phenyl)-amine was obtained in comparable yield analogous to the procedure described for Example 31 step a) using 3-methoxy-5-(trifluoromethyl)-aniline instead of 5-amino-2-chlorobenzotrifluoride and was used directly in the next step.
The title compound, MS (ISP): 314.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using isopropyl-(3-methoxy-5-trifluoromethyl-phenyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 264.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 3-(chlorophenyl)-isopropyl-amine instead of N-ethylaniline and 4-formyl-2-methylimidazole instead of 4-formylimidazole.
The title compound, MS (ISP): 214.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using N-cyclopropyl-aniline instead of N-ethylaniline.
N-Isopropyl-3-chloro-4-methoxy-aniline (0.20 g, 1.0 mmol) was dissolved in methanol (10 ml). Then 4-formylimidazole (0.288 g, 3.0 mmol) and zinc chloride (0.545 g, 4.0 mmol) were added and the reaction mixture was cooled with an ice bath. After adding sodium cyanoborohydride (0.189 g, 3.0 mmol) the mixture was allowed to stir at 40° C. overnight. After cooling, the reaction mixture was poured onto ammoniumchloride/ice and extracted with ethyl acetate (3 times 20 ml). The organic layer was dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: ethyl acetate/methanol=95:5) to yield a white solid (136 mg, 49%); MS (ISP): 280.0 ((M+H)+.).
The title compound, MS (ISP): 231.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using (R)-2-phenylamino-propan-1-ol instead of N-isopropyl-3-chloro-4-methoxy-aniline.
The title compound, MS (ISP): 231.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using (S)-2-phenylamino-propan-1-ol instead of N-isopropyl-3-chloro-4-methoxy-aniline.
The title compound, MS (ISP): 260.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using (1-methoxymethyl-propyl)-phenyl-amine instead of N-isopropyl-3-chloro-4-methoxy-aniline.
The title compound, MS (ISP): 237.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using (2,2-difluoroethyl)-phenyl-amine instead of N-isopropyl-3-chloro-4-methoxy-aniline.
The title compound, MS (ISP): 292.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using biphenyl-4-yl-isopropylamine instead of N-isopropyl-3-chloro-4-methoxy-aniline.
The title compound, MS (ISP): 232.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using (2-methoxyethyl)-phenyl-amine instead of N-isopropyl-3-chloro-4-methoxy-aniline.
A suspension of phenylboronic acid (0.5 g, 4.1 mmol), copper(II)-acetate-1-hydrate (0.041 g, 0.21 mmol) and molecular sieves (1.5 g, size 0.4 nm, powdered) in dichloromethane (12 ml) was stirred for 5 min. Then 2-(aminomethyl)-1,3-dioxolane (0.211 g, 2.05 mmol) was added and oxygen was bubbled through the mixture for 5 min. The vessel was closed and shaken overnight at room temperature. For workup ethyl acetate (50 ml) and 1 M sodium bicarbonate solution (30 ml) were added and the mixture was shaken. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (SiO2; eluent: heptane/ethyl acetate=90:10) to yield a light yellow oil (105 mg, 14%); MS (EI): 179.1 (M+.).
The title compound, MS (ISP): 260.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using [1,3]dioxolan-2-ylmethyl-phenyl-amine instead of N-isopropyl-3-chloro-4-methoxy-aniline.
The title compound, MS (ISP): 258.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using phenyl-(tetrahydro-furan-2-ylmethyl)-amine instead of N-isopropyl-3-chloro-4-methoxy-aniline.
The title compound, MS (ISP): 266.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using (3-chloro-phenyl)-(2-methoxy-ethyl)-amine instead of N-isopropyl-3-chloro-4-methoxy-aniline.
The title compound, MS (ISP): 295.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using N-(2-anilinoethyl)-methansulfonamide instead of N-ethylaniline.
The title compound, MS (ISP): 306.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 37 using N-isopropyl-3-chloro-aniline instead of N-isopropyl-3-chloro-4-methoxy-aniline and 2-butyl-4-formyl-imidazole instead of 4-formylimidazole.
The title compound, MS (ISP): 257.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using phenyl-(tetrahydro-pyran-4-yl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 263.9; 266.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using tert-butyl-(3-chloro-phenyl)-amine instead of N-ethylaniline.
To a solution of 3-chloroaniline (1.27 g, 10 mmol) in 1,2-dichloroethane (20 ml) were added molecular sieves (4 g, size 0.4 nM) and cyclopropanecarboxyaldehyde (0.7 g, 10 mmol). After stirring the mixture for 5 min at room temperature sodium triacetoxyborohydride (3.18 g, 15 mmol) and acetic acid (0.6 g, 10 mmol) were added. The reaction mixture was stirred at room temperature overnight. For workup dichloromethane (100 ml) and 1 M sodium bicarbonate solution (40 ml) were added and the mixture was shaken. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (heptane/ethyl acetate=9:1) to yield a colourless liquid (1.09 g, 60%); MS (EI): 181.1 (M+.).
The title compound, MS (ISP): 261.9; 263.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-chloro-phenyl)-cyclopropylmethyl-amine instead of N-ethylaniline.
To a solution of 3-chloroaniline (1.27 g, 10 mmol) in 1,2-dichloroethane (20 ml) were added molecular sieves (4 g, size 0.4 nM) and cyclopropyl methyl ketone (0.84 g, 10 mmol). After stirring the mixture for 5 min at room temperature sodium triacetoxyborohydride (3.18 g, 15 mmol) and acetic acid (0.6 g, 10 mmol) were added. The reaction mixture was stirred at room temperature overnight. For workup dichloromethane (100 ml) and 1 M sodium bicarbonate solution (40 ml) were added and the mixture was shaken. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (heptane/ethyl acetate=9:1) to yield a colourless liquid (0.083 g, 4.5%); MS (ISP): 196.3 (M+H)+.).
The title compound, MS (ISP): 276.0; 277.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-chloro-phenyl)-(1-cyclopropylethyl)-amine instead of N-ethylaniline.
The title compound, MS (ISP): 268.1 ((M+H)+.) was obtained analogous to the procedure described for Example 1 using (3-chloro-4-fluoro-phenyl)-isopropyl-amine instead of N-ethylaniline.
To a solution of 3-chloroaniline (1.27 g, 10 mmol) in 1,2-dichloroethane (20 ml) were added molecular sieves (4 g, size 0.4 nM) and 4-(tert-butyldimethylsilyloxy)-cyclohexanone (4.57 g, 20 mmol). After stirring the mixture for 30 min at room temperature sodium triacetoxyborohydride (8.48 g, 40 mmol) and acetic acid (1.2 g, 20 mmol) were added. The reaction mixture was stirred at room temperature overnight. For workup dichloromethane (100 ml) and 1 M sodium bicarbonate solution (40 ml) were added and the mixture was shaken. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (heptane/ethyl acetate=1:1) to yield a colourless liquid (0.80 mg, 23.5%); MS (EI): 339.2; 341.3 (M+.).
To a solution of [4-(tert-butyl-dimethyl-silanyloxy)-cyclohexyl]-(3-chloro-phenyl)-amine (0.68 g, 20 mmol) in 1,2-dichloroethane (10 ml) were added molecular sieves (2 g, size 0.4 nM) and 4-formyl-imidazole (0.50 g, 5.2 mmol). After stirring the mixture for 30 min at room temperature sodium triacetoxyborohydride (1.70 g, 8 mmol) and acetic acid (0.24 g, 4 mmol) were added. The reaction mixture was stirred at room temperature overnight. For workup dichloromethane (50 ml) and 1 M sodium bicarbonate solution (30 ml) were added and the mixture was shaken. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (heptane/ethyl acetate=1:1) to yield a 0.3 g of a white solid. This compound was dissolved in tetrahydrofuran (5 ml), tetrabutylammonium fluoride solution (1M in tetrahydrofuran, 2 ml) was added at 0° C., and the mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was mixed with water and ethyl acetate. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (ethyl acetate/methanol=9:1) to yield a white foam (0.14 mg, 65%); MS (ISP): 306.2 (M+H)+).
4-Chloroaniline (0.26 g, 2.0 mmol) was dissolved in methanol (25 ml). Then 3-oxetanone (0.22 g, 3 mmol) and zinc chloride (1.09 g, 8.0 mmol) were added and the reaction mixture was cooled with an ice bath. After adding sodium cyanoborohydride (0.377 g, 6.0 mmol) the mixture was allowed to stir at 40° C. for 5 hours. After cooling, the reaction mixture was poured onto ammonium chloride/ice and extracted with ethyl acetate (3 times 20 ml). The organic layer was dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (heptane/ethyl acetate=95:5) to yield a light yellow liquid (108 mg, 29%); 1H-NMR (CDCl3): 4.14 b, 1H(NH); 4.55 m, 3H(CHO, CHN); 5.00 t, 2H(CHO), 6.43 d, 2H (aryl-H) and 7.15 d, 2H (aryl-H).
The title compound, MS (ISP): 264.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (4-chloro-phenyl)-oxetan-3-yl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 236.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-chlorophenyl)-methyl-amine instead of N-ethylaniline and 4-acetylimidazole instead of 4-formylimidazole.
The title compound, MS (ISP): 236.1; 238.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (4-chlorophenyl)-ethyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 238.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3,4-difluorophenyl)-ethyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 246.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (benzo[1,3]dioxol-5-yl)-ethyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 234.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (2-fluorophenyl)-isopropyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 234.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (3-fluorophenyl)-isopropyl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 234.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using (4-fluorophenyl)-isopropyl-amine instead of N-ethylaniline.
To a solution of 2-methoxyaniline (0.62 g, 5 mmol) in methanol (5 ml) was added 4-formylimidazole (0.48 g, 5 mmol). After stirring the mixture overnight at 60° C. the solution was cooled and sodium borohydride (0.28 g, 7.5 mmol) were added. The reaction mixture was stirred at room temperature for 4 hours. Then water was added and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate and evaporated. The residue was purified by recrystallisation from heptane/ethyl acetate to yield off-white crystals (0.85 mg, 84%); MS (ISP): 204.3 ((M+H)+.).
The title compound, MS (ISP): 252.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-methylsulfonyl-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 225.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 6-aminoquinoline instead of 2-methoxyaniline.
The title compound, MS (ISP): 230.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 2-isopropyl-6-methylaniline instead of 2-methoxyaniline.
To a solution of 4-trifluoromethoxyaniline (0.89 g, 5 mmol) in methanol (5 ml) was added 4-formylimidazole (0.48 g, 5 mmol). After stirring the mixture overnight at 60° C. the solution was cooled and sodium borohydride (0.28 g, 7.5 mmol) were added. The reaction mixture was stirred at room temperature for 4 hours. Then water was added and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column filtration (heptane/ethyl acetate=1:1) to yield a light yellow liquid (1.0 g, 78%); MS (ISP): 258.1 ((M+H)+.).
To a solution of (3H-imidazol-4-ylmethyl)-(4-trifluoromethoxy-phenyl)-amine (0.39 g, 1.5 mmol) in 1,2-dichloroethane (5 ml) were added successively 2-methoxypropene (0.16 g, 2.25 mmol), trifluoroacetic acid (0.26 g, 2.25 mmol) and sodium triacetoxyborohydride (0.48 g, 2.25 mmol). After stirring the mixture overnight at 60° C. 1 M sodium hydroxide solution (5 ml) was added and the mixture was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography (heptane/ethyl acetate=1:1) to yield a white solid (0.24 g, 53%); MS (ISP): 300.1 ((M+H)+.).
The title compound, MS (ISP): 260.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-methoxymethyl-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 280.3 ((M-CH3)+); 294.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-methanesulfonyl-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 266.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 2-aminonaphthaline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 267.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 6-aminoquinoline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 247.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 5-amino-2-methoxypyridine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 256.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using indan-5-ylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 176.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using pyrazin-2-ylamine instead of 2-methoxyaniline.
The title compound, MS (ISP): 208.8; 210.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-amino-2-chloro-pyridine instead of 2-methoxyaniline.
The title compound, MS (ISP): 268.3, 270.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-chloro-5-fluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 252.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3,4-difluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 268.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 5-chloro-2-fluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 268.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-chloro-2-fluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 264.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-fluoro-4-methoxyaniline instead of 4-trifluoromethoxyaniline in step a).
To a solution of 3-chloro-2-fluoroaniline (0.44 g, 3 mmol) in methanol (5 ml) was added 4-formylimidazole (0.29 g, 3 mmol). After stirring the mixture overnight at 60° C. the solution was cooled and sodium borohydride (0.57 g, 15 mmol) was added. The reaction mixture was stirred at room temperature for 4 hours. Then water was added and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column filtration (heptane/ethyl acetate=1:1) to yield a light yellow liquid (0.55 mg, 81%); MS (ISP): 226.3 ((M+H)+.).
(3-Chloro-2-fluoro-phenyl)-(3H-imidazol-4-ylmethyl)-amine (0.24 g, 1 mmol) was dissolved in methanol (15 ml). Then acetaldehyde (0.28 ml, 5 mmol), zinc chloride (0.55 g, 4 mmol) and sodium cyanoborohydride (0.19 g, 3 mmol) were added and the reaction mixture was allowed to stir at 40° C. overnight. After cooling, the reaction mixture was poured onto ammoniumchloride/ice and extracted with ethyl acetate (2 times 50 ml). The organic layer was dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (SiO2; eluent: heptane/ethyl acetate=90:10) to yield a light yellow oil (0.16 g, 63%); MS (ISP): 254.1 ((M+H)+.).
The title compound, MS (ISP): 252.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 2-naphthylamine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 261 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-nitronaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 237.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-amino-2-chloropyridine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 233.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-amino-2-methoxypyridine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 236.8; 238.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 5-amino-2-chloropyridine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 250.9; 252.9 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 5-amino-2-chloropyridine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 217.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 2-aminopyridine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 267.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 8-aminoquinoline instead of 4-trifluoromethoxyaniline in step a).
To sodium hydride (149 mg, 55% in mineral oil, 3.42 mmol) in tetrahydrofuran (240 ml) was added a solution of (3H-imidazol-4-ylmethyl)-isopropyl-(3-nitro-phenyl)-amine (685 mg, 2.63 mmol) in tetahydrofuran (100 ml) and stirring was continued for 45 min at room temperature. The reaction mixture was cooled with an ice bath and 2-(trimethylsilyl)ethoxymethylchloride (439 mg, 2.63 mmol) was added. After stirring the suspension overnight the reaction was quenched with saturated sodium bicarbonate solution. Tetrahydrofuran was evaporated and the residue was extracted with ethyl acetate twice. The combined organic layers were washed with water, dried over magnesium sulphate and evaporated. The residue was purified using flash chromatography (SiO2; eluent: heptane/ethyl acetate=80:20) to yield a light yellow oil, (0.20 g, 20%); MS (ISP): 391.3 ((M+H)+.).
Isopropyl-(3-nitro-phenyl)-[3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazol-4-ylmethyl]-amine (0.2 g, 0.51 mmol) was dissolved in ethanol, palladium on charcoal (20 mg, 10% Pd) was added and the mixture was hydrogenated overnight. The catalyst was filtered off and the solvent was evaporated. The residue was dissolved in ethyl acetate and filtered over silica gel. After evaporation the residue was dissolved in hydrochloric acid in ethanol (5M, 1 ml) and stirred at 60° C. for 2 hours. The solvent was evaporated and the residue was partitioned between sodium hydroxide solution (10%) and dichloromethane. After separation the aqueous layer was extracted again with dichloromethane. The combined organic layers were dried over magnesium sulphate and evaporated. The residue was purified using flash chromatography (column: Isolute® Flash-NH2 from Separtis; eluent: ethyl acetate/methanol=90:10) to yield a light yellow gum, (0.054 g, 51%); MS (ISP): 231.4 ((M+H)+.).
The title compound, MS (ISP): 263.9 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 5-fluoro-2-methoxy-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 251.9 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 2,5-difluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 251.9 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-bromo-3-fluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 250.3; 252.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 2-chloroaniline instead of 3-chloro-2-fluoroaniline and 4-formyl-2-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 250.1; 252.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 4-chloroaniline instead of 3-chloro-2-fluoroaniline and 4-formyl-2-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 246.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-methoxyaniline instead of 3-chloro-2-fluoroaniline and 4-formyl-2-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 216.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using aniline instead of 3-chloro-2-fluoroaniline and 4-formyl-2-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 264.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-chloroaniline instead of 4-trifluoromethoxyaniline and 4-formyl-2-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 230.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using aniline instead of 4-trifluoromethoxyaniline and 4-formyl-2-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 260.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-methoxyaniline instead of 4-trifluoromethoxyaniline and 4-formyl-2-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 252.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3,5-difluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 282.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 2,4-difluoro-3-methoxyaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 302.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-fluoro-4-trifluoromethyl-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 250.1 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 2-chloroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 249.9 ((M+H)+.) was obtained analogous to the procedure described for Example 81 using 4-chloroaniline instead of 3-chloro-2-fluoroaniline and 4-formyl-5-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 230.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using aniline instead of 4-trifluoromethoxyaniline and 4-formyl-5-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 260.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-methoxyaniline instead of 4-trifluoromethoxyaniline and 4-formyl-5-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 270.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 2,3,4-trifluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 248.2 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-trifluoro-3-methylaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 274.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-isopropoxyaniline instead of 4-trifluoromethoxyaniline in step a).
Isopropyl-(3-nitro-phenyl)-[3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazol-4-ylmethyl]-amine (0.055 g, 0.14 mmol) was dissolved in ethanol, palladium on charcoal (20 mg, 10% Pd) was added and the mixture was hydrogenated overnight. The catalyst was filtered off and the solvent was evaporated. The residue was dissolved in ethyl acetate and filtered over silica gel. After evaporation the residue was dissolved in toluene (1.5 ml) and tetrahydrofuran (3 ml), acetic anhydride (0.015 mg, 0.14 mmol) was added and the mixture was stirred overnight. The solvents were evaporated and the residue was partitioned between sodium bicarbonate solution and ethyl acetate. The organic layer was dried over magnesium sulphate and evaporated. The residue was dissolved in tetrahydrofuran (5 ml) and tetrabutylammonium fluoride solution (0.3 ml, 1M) in tetrahydrofuran was added. After stirring the mixture at 65° C. overnight the solvent was evaporated and the residue was purified by flash chromatography (column: Isolute® Flash-NH2 from Separtis; eluent: ethyl acetate/methanol=95:5) to yield a white gum, (0.005 g, 34%); MS (ISP): 273.2 ((M+H)+.).
The title compound, MS (ISP): 247.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-amino-2-methoxypyridine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 247.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 2-amino-6-methoxypyridine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 322.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-benzyloxy-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 300.1 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-trifluoromethoxyaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 260.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-methoxyaniline instead of 4-trifluoromethoxyaniline and 4-formyl-1-methyl-imidazole instead of 4-formylimidazole in step a).
The title compound, MS (ISP): 264.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-fluoro-3-methoxyaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 276.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3,5-dimethoxyaniline instead of 4-trifluoromethoxyaniline in step a).
(3-Benzyloxy-phenyl)-(3H-imidazol-4-ylmethyl)-isopropyl-amine (0.109 g, 0.34 mmol) was dissolved in ethanol (10 ml), palladium on charcoal (10 mg, 10% Pd) was added and the mixture was hydrogenated overnight at room temperature. The catalyst was filtered off and the solvent was evaporated. The residue was purified by flash chromatography (column: Isolute® Flash-NH2 from Separtis; eluent: ethyl acetate/methanol=95:5) to yield a white foam, (0.042 g, 53%); MS (ISP): 232.1 ((M+H)+.).
The title compound, MS (ISP): 259.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-amino-benzoylmethylamide instead of 3-chloro-2-fluoroaniline in step a).
[3-tert-Butyl-dimethyl-silanyloxymethyl]phenyl]-(3H-imidazol-4-ylmethyl)-isopropyl-amine, MS (ISP): 228.4 ((M-TBDMSO)+.), 360.5 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-(tert-butyl-dimethylsilanyloxymethyl)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
[3-tert-Butyl-dimethyl-silanyloxymethyl]phenyl]-(3H-imidazol-4-ylmethyl)-isopropyl-amine (0.724 g, 2 mmol) was dissolved in tetrahydrofuran (20 ml) and tetrabutylammonium fluoride solution (4 ml, 1M) in tetrahydrofuran was added. After stirring the mixture at room temperature overnight the solvent was evaporated and the residue was purified by flash chromatography (SiO2, eluent: ethyl acetate) to yield a colourless gum, (0.252 g, 51%); MS (ISP): 246.4 ((M+H)+.).
The title compound, MS (ISP): 260.1 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-ethoxyaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 308.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-phenoxyaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 282.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-difluoromethoxyaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 332.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 1,1,2,2-tetrafluoro-ethoxy-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 321.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-chloro-4-morpholin-4-yl-phenylamine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 335.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-chloro-4-morpholin-4-yl-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 264.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-chloro-4-methylaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 264.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 2-fluoro-3-methoxy-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 230.3 ((M+H)+.) was obtained analogous to the procedure described for Example 81 using 3,4-dimethylaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 313.3 ((M+H)+.) was obtained analogous to the procedure described for Example 81 using 1-(4-amino-3-fluoro-phenyl)-1H-pyridin-2-one instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 327.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 1-(4-amino-3-fluoro-phenyl)-1H-pyridin-2-one instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 356.5 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-benzyloxy-3-chloroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 342.1 ((M+H)+.) was obtained analogous to the procedure described for Example 81 using 4-benzyloxy-3-chloroaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 309.6 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-(pyridine-3-yloxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 308.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-phenoxyaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 364.2 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 2-methoxy-5-(1-methyl-1-phenyl-ethyl)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 376.1 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-chloro-4-(4-chloro-phenoxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 362.3 ((M+H)+.) was obtained analogous to the procedure described for Example 81 using 3-chloro-4-(4-chloro-phenoxy)-phenylamine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 338.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-(2-methoxy-phenoxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 306.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-benzylaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 292.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-aminobiphenyl instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 267.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 2-phenoxy-pyridin-4-yl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 301.1; 303.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 6-(4-chloro-phenoxy-pyridin-3-yl-amine instead of N-ethylaniline.
The title compound, MS (ISP): 329.1; 331.1 ((M+H)+.) was obtained analogous to the procedure described for Example 81 using 6-(4-chloro-phenoxy-pyridin-3-yl-amine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 376.3 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-(4-trifluoromethoxy-phenoxy)-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 338.5 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-(4-methoxy-phenoxy)-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 338.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-(2-methoxy-phenoxy)-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 342.1 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-(4-chloro-phenoxy)-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 324.5 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-phenylsulfanyl-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 376.2; 378.1 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-(3,4-dichloro-phenoxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 342.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-(4-chloro-phenoxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 342.1 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 4-(2-chloro-phenoxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 322.4 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-amino-benzophenone instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 265.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 4-aminodiphenylamine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 308.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 4-benzyloxyaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 354.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-[2-(4-chloro-phenyl)-ethyl]-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 322.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-benzyloxyaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 307.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-aminodiphenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 313.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 1-(4-amino-benzyl)-pyrrolidin-2-one instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 304.5 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 4-[2-(4-chloro-phenyl)-ethyl]-phenylamine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 299.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 1-(4-amino-benzyl)-pyrrolidin-2-one instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 307.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-pyridin-4-ylmethyl-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 321.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 4-aminodiphenylamine instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 376.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-chloro-4-(2-chloro-phenoxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 362.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-chloro-4-(2-chloro-phenoxy)-phenylamine instead of 3-chloro-2-fluoroaniline in step a).
C-{4-[(1H-Imidazol-4-ylmethyl)-isopropyl-amino]-phenyl}-N-methyl-methanesulfonamide
The title compound, MS (ISP): 323.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using C-(4-amino-phenyl)-N-methyl-methanesulfonamide instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 309.5 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using C-(4-amino-phenyl)-N-methyl-methanesulfonamide instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 344.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-chloro-4-(2-pyrimidinyloxy)phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 311.9; 314.0 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-bromo-4-fluoroaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 294.2 ((M+H)+.) was obtained analogous to the procedure described for Example 67 using 3-pyrimidin-5-yl-phenyl-amine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 306.5 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-benzylaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 292.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 4-benzylaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 266.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-phenoxy-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 280.5 ((M+H)+.) was obtained analogous to the procedure described for Example 81 using 3-phenoxyaniline instead of 3-chloro-2-fluoroaniline in step a) and formaldehyde instead of acetaldehyde in step b).
The title compound, MS (ISP): 280.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-benzyloxy-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 204.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-methoxy-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 343.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-chloro-4-(pyridin-4-yloxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 228.1 ([37Cl M+H]+.), 226.1 ([35Cl M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-chloro-5-fluoro-aniline instead of 2-methoxyaniline.
To a solution of 3,4-difluoroaniline (0.60 g, 4.65 mmol) in 1,2-dichloroethane (5 ml) were added 4-formylimidazole (0.67 g, 6.97 mmol), sodium triacetoxyborohydride (1.97 g, 9.29 mmol) and acetic acid (0.05 ml). The reaction mixture was stirred at 50° C. for 4 h. The reaction mixture was then concentrated in vacuo and the residue was purified using flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: methanol/dichloromethane gradient) to yield an off-white solid (284 mg, 29%); MS (ISP): 210.1 ((M+H)+.).
The title compound, MS (ISP): 272.1 ([81Br M+H]+), 270.1 ([79Br M+H]+), was obtained in comparable yield analogous to the procedure described for Example 180 using 4-bromo-3-fluoro-aniline instead of 3,4-difluoro-aniline.
To a stirred solution of 3-[1,3]dioxolan-2-yl-2,4-difluoro-phenylamine (0.41 g, 1.94 mmol) in methanol (10 ml) was added 4-formyl-imidazole-1-sulfonic acid dimethylamide (0.46 g, 2.24 mmol) and the mixture was heated at 60° C. for 18 h. After cooling to room temperature sodium borohydride (0.39 g, 10.3 mmol) was added and the mixture stirred at room temperature for 2 h. The mixture was concentrated in vacuo and the residue was purified by flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: ethyl acetate/cyclohexane gradient) to yield a light brown gum (604 mg, 76%); MS (ISP): 389.1 ((M+H)+.).
To a stirred solution of 5-[(3-[1,3]dioxolan-2-yl-2,4-difluoro-phenylamino)-methyl]-imidazole-1-sulfonic acid dimethylamide (0.60 g, 1.53 mmol) in methanol (20 ml) were added acetaldehyde (0.43 ml, 7.61 mmol), zinc chloride (6.13 mmol) and sodium cyanoborohydride (0.29 g, 4.60 mmol) and the mixture was heated at 40° C. for 18 h. The mixture was then concentrated in vacuo and the residue taken up in ethyl acetate and washed with saturated aq. ammonium chloride solution. The layers were separated and the aqueous phase was back extracted twice with ethyl acetate. The combined organic phases were washed sequentially with water and with saturated brine, then dried over magensium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: ethyl acetate/cyclohexane gradient) to yield a colourless viscous oil (538 mg, 84%); MS (ISP): 417.3 ((M+H)+.).
To a stirred solution of 5-[(3-[1,3]dioxolan-2-yl-2,4-difluoro-phenylamino)-methyl]-imidazole-1-sulfonic acid dimethylamide (0.53 g, 1.27 mmol) in tetrahydrofuran (10 ml) was added a 4 N solution of hydrogen chloride in dioxane (3.87 ml, 15.5 mmol) and the mixture was stirred at room temperature for 24 h. The mixture was then concentrated in vacuo and the residue taken up in dichloromethane/methanol (95:5) and washed with 1 N aq. sodium hydroxide solution. The layers were separated and the aqueous phase was back extracted twice with dichloromethane/methanol (95:5). The combined organic phases were washed with saturated brine, then dried over magensium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: methanol/dichloromethane gradient) to yield a colourless gum (225 mg, 57%); MS (ISP): 310.3 ((M+H)+.).
To a stirred solution of (3-[1,3]dioxolan-2-yl-2,4-difluoro-phenyl)-ethyl-(3H-imidazol-4-ylmethyl)-amine (0.22 g, 0.70 mmol) in tetrahydrofuran (5 ml) was added a 3 N aqueous solution of hydrochloric acid (0.93 ml, 2.79 mmol) and the mixture was stirred at room temperature for 48 h. The mixture was then concentrated in vacuo and the residue taken up in ethyl acetate and washed with 1 N aq. sodium hydroxide solution. The layers were separated and the aqueous phase was back extracted twice with ethyl acetate. The combined organic phases were washed with saturated brine, then dried over magensium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: methanol/dichloromethane gradient) to yield a yellow gum (111 mg, 48%); MS (ISP): 266.0 ((M+H)+.).
To a stirred solution of 3-[ethyl-(3H-imidazol-4-ylmethyl)-amino]-2,6-difluoro-benzaldehyde (0.10 g, 0.39 mmol) in methanol (3 ml) was added sodium borohydride (0.06 g, 1.56 mmol) and the mixture was stirred at room temperature for 5 h. The mixture was concentrated in vacuo and the residue was purified by flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: methanol/dichloromethane gradient) to yield a colourless gum (604 mg, 76%); MS (ISP): 268.3 ((M+H)+.).
The title compound, MS (ISP): 272.1 ([81Br M+H]+), 270.1 ([79Br M+H]+), was obtained in comparable yield analogous to the procedure described for Example 180 using 3-bromo-4-fluoro-aniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 240.1 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-(difluoromethoxy)-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 222.1 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 4-fluoro-3-methoxy-aniline instead of 2-methoxyaniline.
To a solution of m-anisidine (0.91 ml, 8.12 mmol) in methanol (25 ml) was added 4-formylimidazole (0.86 g, 8.93 mmol). After stirring the mixture overnight at room temperature sodium borohydride (0.46 g, 12.2 mmol) was added. The reaction mixture was then concentrated in vacuo. The residue was purified using flash chromatography (column: Isolute® Flash-NH2 from Separtis; eluent: methanol/dichloromethane 9:1) to yield a white solid (1.34 g, 18%); MS (ISP): 204.1 ([M+H]+).
(3H-Imidazol-4-ylmethyl)-(3-methoxy-phenyl)-amine (0.070 g, 0.34 mmol) was dissolved in acetonitrile (10 ml). Then formaldehyde (0.0.06 ml, 0.86 mmol, 37% aqueous solution) and sodium cyanoborohydride (0.065 g, 1.03 mmol) were added and the reaction mixture was allowed to stir at room temperature for 10 minutes. The reaction mixture was then acidified to pH 2-3 by dropwise addition of concentrated hydrochloric acid whereupon precipitation occurred. The mixture was stirred for a further 1 h at room temperature before being concentrated in vacuo. The residue was taken up in ethyl acetate, washed with 1 M aqueous sodium hydroxide solution and the organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was purified using flash chromatography (column: Isolute® Flash-NH2 from Separtis; eluent: methanol/dichloromethane gradient) to yield a white solid (0.056 g, 75%); MS (ISP): 218.3 ([M+H]+).
The title compound, MS (ISP): 321.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-(2-pyridin-4-yl-ethyl)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 294.1 ([M+H]+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-phenoxyaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 254.3 ((M+H)+.) was obtained analogous to the procedure described for Example 186 using 3-(difluoromethoxy)aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 294.1 ((M+H)+.) was obtained analogous to the procedure described for Example 186 using 3-benzyloxyaniline instead of m-anisidine in step a).
The title compound, MS (ISP): 236.1 ((M+H)+.) was obtained analogous to the procedure described for Example 186 using 4-fluoro-3-methoxyaniline instead of m-anisidine in step a).
The title compound, MS (ISP): 308.4 ([M+H]+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-benzyloxyaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 232.1 ([M+H]+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-methoxyaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 250.1 ([M+H]+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 4-fluoro-3-methoxyaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 268.3 ([M+H]+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-(difluoromethoxy)aniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 459.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-[(1-methyl-4-(piperidinyl)oxy)]-phenylamine instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 307.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 4-(2-pyridin-4-yl-ethyl)-phenylamine instead of 3-chloro-2-fluoroaniline in step a).
To a solution of (3H-imidazol-4-ylmethyl)-(3-methoxy-phenyl)-amine (0.05 g, 0.25 mmol, Example 186 step a) in 1,2-dichloroethane (2 ml) were added pyridine-4-carbaldehyde (0.06 ml, 0.64 mmol) and sodium triacetoxyborohydride (0.21 g, 0.98 mmol). The reaction mixture was stirred at 40° C. for 72 h. The reaction mixture was then concentrated in vacuo and the residue was purified using flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: methanol/dichloromethane gradient) to yield a yellow oil (7 mg, 10%); MS (ISP): 295.3 ((M+H)+.).
The title compound, MS (ISP): 240.1 ([37Cl M+H]+), 238.1 ([35Cl M+H]+), was obtained in comparable yield analogous to the procedure described for Example 180 using 4-chloro-3-methoxy-aniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 300.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-chloro-phenoxy-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 280.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-phenoxymethyl-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 284.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 4-fluoro-3-phenoxy-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 205.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 4-amino-2-methoxypyridine instead of 2-methoxyaniline.
The title compound, MS (ISP): 280.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-chloro-3-methoxy-phenylamine instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 306.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 5-amino-1,3-dihydrobenzo[c]thiophene 2,2-dioxide instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 342.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-(3-chloro-phenoxy)-phenylamine instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 322.5 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-phenoxymethyl-phenylamine instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 326.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-fluoro-3-phenoxy-phenylamine instead of 4-trifluormethoxyaniline in step a).
To a solution of 3-benzyloxyaniline (0.70 g, 3.51 mmol) in 1,2-dichloroethane (10 ml) were added 6-bromo-pyridine-2-carboxaldehyde (0.65 g, 3.51 mmol), sodium triacetoxyborohydride (1.49 g, 7.03 mmol) and acetic acid (0.80 ml, 14.1 mmol). The reaction mixture was shaken at 40° C. overnight. For work-up dichloromethane (100 ml) and 1 M sodium bicarbonate solution (40 ml) were added and the mixture was shaken. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (heptane/ethyl acetate=3:1) to yield an orange oil (1.03 g, 80%); MS (ISP): 371.1 ([81Br M+H]+), 369.1 ([79Br M+H]+).
(3-Benzyloxy-phenyl)-(6-bromo-pyridin-2-ylmethyl)-amine (0.10 g, 0.27 mmol) was dissolved in methanol (2 ml). Then 4-formylimidazole (0.13 g, 1.35 mmol), zinc chloride (0.15 g, 1.08 mmol) and sodium cyanoborohydride (0.05 g, 0.81 mmol) were added and the reaction mixture was allowed to stir at 40° C. overnight. After cooling, the reaction mixture was poured onto ammoniumchloride/ice and extracted with ethyl acetate (2 times 50 ml). The organic layer was dried over magnesium sulfate and evaporated. The residue was purified using flash chromatography (SiO2; eluent: methanol/dichloromethane=1:9) to yield an off-white gum (0.11 g, 94%); MS (ISP): 451.1 ([81Br M+H]+), 449.1 ([79Br M+H]+).
To a saturated solution of ethylamine in methanol (40 ml) was added 4-formyl-imidazole-1-sulfonic acid dimethylamide (2.5 g, 12.3 mmol) and the mixture was stirred overnight. Sodium borohydride (0.70 g, 18.5 mmol) was added and the mixture was stirred at room temperature for 3 h. Water was added and the solution was extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and evaporated. The residue was purified by flash chromatography (SiO2: dichloromethane/methanol=9:1) to yield a light yellow oil (0.785 g, 27%); MS (ISP): 233.1 ((M+H)+.).
A solution of 5-ethylaminomethyl-imidazole-1-sulfonic acid dimethylamide (0.527 g, 2.25 mmol), 2-chloro-4-methoxy-pyrimidine (0.217 g; 1.5 mmol) and N,N-diisopropyl ethyl amine (0.51 ml, 3.0 mmol) in isopropanol (2 ml) was heated in a sealed vessel in a microwave oven for 20 min at 160° C. Ethyl acetate (20 ml) and silica gel (1 g) was added and the mixture was evaporated. The residue was purified by flash chromatography, column: Isolute® Flash-NH2 (Separtis); eluent: heptane/ethyl acetate=8:2) to yield a white solid, (0.265 g, 52%); MS (ISP): 341.0 ((M+H)+.).
4-{[Ethyl-(4-methoxy-pyrimidin-2-yl)-amino]-methyl}-imidazole-1-sulfonic acid dimethylamide (0.265 g, 0.78 mmol) was dissolved in aqueous hydrochloric acid (4 N, 2 ml) and the mixture was stirred at 100° C. for 2 hours. After cooling concentrated sodium hydroxide solution was added slowly until basic pH. The mixture was extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and evaporated. The residue was purified by flash chromatography, column: Isolute® Flash-NH2 (Separtis); eluent: heptane/ethyl acetate=1:1) to yield a colorless liquid, (0.10 g, 55%); MS (ISP): 234.3 ((M+H)+.).
The title compound, MS (ISP): 362.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-(1,2,3,4-tetrahydro-naphthalen-1-yloxy)-phenylamine (synthesized in analogy to its 2-chloro derivative as published in WO2007046392) instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 296.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2-chloro-4-phenoxy-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 294.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 4-formyl-2-methylimidazole instead of 4-formyl-imidazole and 3-benzyloxyaniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 328.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2-benzyl-4,6-dichloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
(2-Benzyl-6-chloro-pyrimidin-4-yl)-ethyl-(3H-imidazol-4-ylmethyl)-amine (0.164 g, 0.5 mmol) was dissolved in methanol (3 ml), ammonium formate (0.315 g, 0.5 mmol) and palladium on charcoal (0.164 g, 10% Pd) was added and the mixture was refluxed for one hour. After cooling the catalyst was filtered off and the solvent was evaporated. The residue was purified by flash chromatography (column: Isolute® Flash-NH2 from Separtis; eluent: ethyl acetate/methanol=95:5) to yield a white solid, (0.03 g, 21%); MS (ISP): 294.4 ((M+H)+.).
The title compound, MS (ISP): 296.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2-chloro-6-phenoxy-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 238.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2,4-dichloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b) and chromatographic separation from the 2-chloro-pyrimidin-4-yl isomer before step c).
The title compound, MS (ISP): 238.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2,4-dichloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b) and chromatographic separation from the 4-chloro-pyrimidin-2-yl isomer before step c).
To a solution of 2-amino-4,6-dichloropyrimidine (1.00 g, 7.72 mmol) in dichloromethane (8 ml) were added 4-formylimidazole (0.74 g, 7.72 mmol) and tetraisopropyl orthotitanate (2.86 ml, 9.65 mmol). After stirring the mixture at 40° C. overnight ethanol (8 ml) and sodium borohydride (0.38 g, 10.0 mmol) were added. The reaction mixture was stirred 40° C. for 7 hours. Then mixture was concentrated in vacuo and the residue was purified by flash chromatography (methanol/dichloromethane gradient) to yield white crystals (43 mg, 26%); MS (EI): 247.1 (37Cl M+.), 245.1 (37Cl35Cl M+.), 243.1 (35Cl M+.).
The title compound, MS (ISP): 190.4 ([M+H]+), was obtained in comparable yield analogous to the procedure described for Example 219 using 2-amino-4-methylpyrimidine instead of 2-amino-4,6-dichloropyrimidine.
The title compound, MS (ISP): 214.1 ([M+H]+), was obtained in comparable yield analogous to the procedure described for Example 180 using 4-cyclopropyl-aniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 214.1 ([M+H]+), was obtained in comparable yield analogous to the procedure described for Example 180 using 3-cyclopropyl-aniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 256.3 ([M+H]+.) was obtained analogous to the procedure described for Example 67 step b) using (4-cyclopropyl-phenyl)-(1H-imidazol-4-ylmethyl)-amine (Example 221) instead of (3H-imidazol-4-ylmethyl)-(4-trifluoromethoxy-phenyl)-amine.
The title compound, MS (ISP): 256.3 ([M+H]+.) was obtained analogous to the procedure described for Example 67 step b) using (3-cyclopropyl-phenyl)-(1H-imidazol-4-ylmethyl)-amine (Example 222) instead of (3H-imidazol-4-ylmethyl)-(4-trifluoromethoxy-phenyl)-amine.
The title compound, MS (ISP): 252.2, 254.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-bromoaniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 320.1; 322.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-bromo-5-trifluoromethyl-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 199.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-amino-benzonitrile instead of 2-methoxyaniline.
The title compound, MS (ISP): 216.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-isopropylaniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 345.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2,4-dichloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b) and chromatographic separation from the 4-chloro-pyrimidin-2-yl isomer without performing step c) at the end.
To sodium hydride (0.194 g, 55% in mineral oil, 4.4 mmol) in dimethylformamide (1.5 ml) was added phenol (0.418 g, 4.4 mmol) and stirring was continued for 15 min at room temperature. To this reaction mixture 4-{[(2-chloro-pyrimidin-4-yl)-ethyl-amino]-methyl}-imidazole-1-sulfonic acid dimethylamide (0.153 g, 0.44 mmol) was added. After stirring and heating to 80° C. overnight the solvent was evaporated. Water was added (5 ml) and the mixture was extracted with ethyl acetate (20 ml) twice. The combined organic layers were washed with water, dried over magnesium sulphate and evaporated. The residue was purified using flash chromatography (SiO2; eluent: heptane/ethyl acetate=95:5) to yield the title compound as a colourless gum, MS (ISP): 403.4 ((M+H)+.).
To remove the dimethylaminosulfonyl protecting group 4-{[ethyl-(2-phenoxy-pyrimidin-4-yl)-amino]-methyl}-imidazole-1-sulfonic acid dimethylamide (65 mg, 0.16 mmol) was dissolved in hydrochloric acid in ethanol (5 N, 1 ml) and the mixture was stirred at 100° C. for 2 hours. For workup aqueous sodium hydroxide solution (0.5 ml, 1 N) was added to basic pH and the mixture was extracted three times with dichloromethane. The combined organic layers were dried over magnesium sulfate and evaporated. The residue was purified by flash chromatography (SiO2; ethyl acetate/methanol=95:5) to yield a white solid, (0.022 g, 46%); MS (ISP): 296.3 ((M+H)+.).
The title compound, MS (ISP): 256.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2,4-dichloro-5-fluoro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 204.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2-chloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 238.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 4,6-dichloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 252.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 4,6-dichloro-2-methyl-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 272.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2-chloro-4-(trifluoromethyl)-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 204.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 215 using (6-chloro-pyrimidin-4-yl)-ethyl-(1H-imidazol-4-ylmethyl)-amine instead of (2-benzyl-6-chloro-pyrimidin-4-yl)-ethyl-(3H-imidazol-4-ylmethyl)-amine.
The title compound, MS (ISP): 218.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 215 using (6-chloro-2-methyl-pyrimidin-4-yl)-ethyl-(1H-imidazol-4-ylmethyl)-amine instead of (2-benzyl-6-chloro-pyrimidin-4-yl)-ethyl-(3H-imidazol-4-ylmethyl)-amine.
The title compound, MS (ISP): 272.5 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2,4,6-trichloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b) and chromatographic separation from the 2,6-dichloro-pyrimidin-2-yl isomer before step c).
The title compound, MS (ISP): 272.8 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2,4,6-trichloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b) and chromatographic separation from the 4,6-dichloro-pyrimidin-2-yl isomer before step c).
The title compound, MS (ISP): 248.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a).
The title compound, MS (ISP): 253.0; 255.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 2-amino-6-bromopyridine instead of 2-methoxyaniline.
The title compound, MS (ISP): 189.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 2-amino-4-methylpyridine instead of 2-methoxyaniline.
The title compound, MS (ISP): 294.1; 296.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-bromoaniline instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 362.1; 364.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-bromo-5-trifluoromethyl-aniline instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 295.1; 297.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 2-amino-6-bromopyridine instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 258.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-isopropylaniline instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 231.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 2-amino-4-methylpyridine instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 274.1 ([37Cl M+H]+.), 272.1 ([37Cl35Cl M+H]+.), 270.2 ([35Cl M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 81 using 3,4-dichloroaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 254.1 ([37Cl M+H]+.), 252.1 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 186 using 4-chloro-3-methoxyaniline instead of m-anisidine in step a).
The title compound, MS (ISP): 252.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 229 using 2,4-dichloro-5-fluoro-pyrimidine instead of 2,4-dichloro-pyrimidine in step a) and sodium methoxide in 1,2-dimethoxyethane instead of sodium hydride/phenol in dimethylformamide in step b).
The title compound, MS (ISP): 247.9 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 229 using sodium methoxide in 1,2-dimethoxyethane instead of sodium hydride/phenol in dimethylformamide in step b).
The title compound, MS (ISP): 271.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2-bromo-6-(trifluoromethyl)-pyridine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 259.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-morpholin-4-yl-phenylamine instead of 2-methoxyaniline.
The title compound, MS (ISP): 241.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-aminobenzonitrile instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 246.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 4,6-dimethyl-2-chloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 292.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 2,4-dichloro-6,7-dihydro-5H-cyclopentapyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 308.4 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 2-chloro-4-methyl-6-phenyl-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 338.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 4-chloro-2-(4-methoxy-phenyl)-6-methyl-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 352.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 4-chloro-2-[(1E)-2-(3-fluoro-phenyl)-vinyl]-6-methyl-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 320.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 2,4-dichloro-6-trifluoromethyl-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b) and chromatographic separation from the 2-chloro-6-trifluoromethyl-pyrimidin-4-yl isomer before step c).
The title compound, MS (ISP): 320.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 2,4-dichloro-6-trifluoromethyl-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b) and chromatographic separation from the 4-chloro-6-trifluoromethyl-pyrimidin-2-yl isomer before step c).
The title compound, MS (ISP): 257.1 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 1-(3-amino-phenyl)-pyrrolidin-2-one instead of 2-methoxyaniline.
The title compound, MS (ISP): 228.1 ([M+H]+.), was obtained analogous to the procedure described for Example 186 using 4-cyclopropyl-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 228.1 ([M+H]+.), was obtained analogous to the procedure described for Example 186 using 3-cyclopropyl-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 239.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-pyrrol-1-yl-phenylamine instead of 2-methoxyaniline.
The title compound, MS (ISP): 240.1 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-(1H-imidazol-1-yl)benzenamine instead of 2-methoxyaniline.
The title compound, MS (ISP): 243.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-pyrrolidin-1-yl-phenylamine instead of 2-methoxyaniline.
The title compound, MS (ISP): 301.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 4-morpholinoaniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 299.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 1-(3-amino-phenyl)-pyrrolidin-2-one instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 281.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-pyrrol-1-yl-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 282.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-(1H-imidazol-1-yl)benzenamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 285.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 3-pyrrolidin-1-yl-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 294.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 1 using 2-(biphenyl-3-ylamino)-ethanol instead of N-ethylaniline.
The title compound, MS (ISP): 262.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 229 using the 4-chloro-pyrimidin-2-yl isomer and sodium ethoxide in 1,2-dimethoxyethane instead of sodium hydride/phenol in dimethylformamide in step b).
The title compound, MS (ISP): 262.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 229 using the 2-chloro-pyrimidin-4-yl isomer and sodium ethoxide in 1,2-dimethoxyethane instead of sodium hydride/phenol in dimethylformamide in step b).
The title compound, MS (ISP): 280.1; 282.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-bromoaniline instead of 3-chloro-2-fluoroaniline in step a).
The title compound, MS (ISP): 192.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 180 using 4-fluoro-aniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 210.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 180 using 3,5-difluoro-aniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 254.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 180 using 2,2-difluoro-5-aminobenzodioxole instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 334.3 (81Br81Br [M+H]+.), 332.3 (81Br79Br [M+H]+.), 330.3 (79Br79Br [M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 180 using 3,4-dibromoaniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 304.0 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 180 using 2,2,3,3-tetrafluoro-6-aminobenzodioxene instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 228.1 (37Cl [M+H]+.), 226.1 (35Cl [M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 180 using 3-chloro-4-fluoro-aniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 310.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 180 using 3,5-bis(trifluoromethyl)-aniline instead of 3,4-difluoro-aniline.
The title compound, MS (ISP): 252.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 2,4-dichloro-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b) and chromatographic separation from the 2-chloro-pyrimidin-4-yl isomer before step c).
The title compound, MS (ISP): 266.0; 268.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 81 using 3-bromoaniline instead of 3-chloro-2-fluoroaniline in step a) and formaldehyde solution (40% in water) instead of acetaldehyde in step b).
The title compound, MS (ISP): 240.1 (37Cl [M+H]+.), 238.0 (35Cl [M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-chloro-4-methoxy-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 228.1 (37Cl [M+H]+.), 226.1 (35Cl [M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-chloro-4-fluoro-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 224.4 ([M+H]+.), was obtained analogous to the procedure described for Example 186 using 3,4-difluoro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 260.0 (37Cl [M+H]+.), 257.9 (37Cl 35Cl [M+H]+.), 256.1 (35Cl [M+H]+.), was obtained analogous to the procedure described for Example 186 using 3,4-dichloro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 206.1 ([M+H]+.), was obtained analogous to the procedure described for Example 186 using 4-fluoro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 268.0 (81Br [M+H]+.), 266.1 (79Br [M+H]+.), was obtained analogous to the procedure described for Example 186 using 4-bromo-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 259.8 (37Cl [M+H]+.), 258.0 (37Cl 35Cl [M+H]+.), 256.1 (35Cl [M+H]+.), was obtained analogous to the procedure described for Example 186 using 3,5-dichloro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 224.4 ([M+H]+.), was obtained analogous to the procedure described for Example 186 using 3,5-difluoro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 268.1 ([M+H]+.), was obtained analogous to the procedure described for Example 186 using 2,2-difluoro-5-amino-benzodioxole instead of m-anisidine in step a).
The title compound, MS (ISP): MS (ISP): 242.2 ([37Cl M+H]+.), 240.1 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 186 using 3-chloro-4-fluoro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): MS (ISP): 242.2 ([37Cl M+H]+.), 240.1 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 186 using 3-chloro-5-fluoro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 296.1 ([81Br M+H]+.), 294.0 ([79Br M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 67 using 4-bromo-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 334.1 ([81Br M+H]+.), 331.9 ([81Br79Br M+H]+), 329.9 ([79Br M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 180 using 3,4-dibromoaniline instead of 3,4-difluoroaniline.
The title compound, MS (ISP): 376.1 ([81Br M+H]+.), 374.1 ([81Br79Br M+H]+.), 372.0 ([79Br M+H]+.), was obtained analogous to the procedure described for Example 67 step b).
The title compound, MS (ISP): 346.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 297 using 2,2,3,3-tetrafluoro-6-aminobenzodioxene instead of 3,4-dibromoaniline in step a).
The title compound, MS (ISP): 270.2 ([37Cl M+H]+.), 268.2 ([35Cl M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 67 using 4-chloro-3-fluoro-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 352.5 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 297 using 3,5-bis(trifluoromethyl)aniline instead of 3,4-dibromoaniline in step a).
To a solution of 4-fluoroaniline (0.60 g, 5.40 mmol) in 1,2-dichloroethane (5 ml) were added 4-formylimidazole (0.78 g, 8.10 mmol), sodium triacetoxyborohydride (2.29 g, 10.8 mmol) and acetic acid (0.06 ml). The reaction mixture was stirred at 50° C. for 4 h. The reaction mixture was then concentrated in vacuo and the residue was purified using flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: methanol/dichloromethane gradient) to yield a white solid (160 mg, 16%); MS (ISP): 192.2 ((M+H)+.).
To a solution of (4-fluoro-phenyl)-(1H-imidazol-4-ylmethyl)-amine (0.20 g, 1.05 mmol) in 1,2-dichloroethane (6 ml) were added acetaldehyde (0.30 ml, 5.23 mmol), sodium triacetoxyborohydride (0.67 g, 3.14 mmol) and acetic acid (0.06 ml). The reaction mixture was stirred at 40° C. for 16 h. The reaction mixture was then concentrated in vacuo and the residue was purified using flash chromatography (column: Isolute® Flash-NH2 (Separtis); eluent: methanol/ethyl acetate/heptane gradient) to yield a white solid (131 mg, 57%); MS (ISP): 220.4 ((M+H)+.).
The title compound, MS (ISP): 254.0 ([81Br M+H]+.), 252.1 ([79Br M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 4-bromoaniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 282.1 ([81Br M+H]+.), 280.0 ([79Br M+H]+.), was obtained analogous to the procedure described for Example 301 step b).
The title compound, MS (ISP): 274.0 ([37Cl M+H]+.), 272.1 ([37Cl 35Cl M+H]+.), 270.2 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 301 using 3,5-dichloro-aniline instead of 4-fluoroaniline in step a).
The title compound, MS (ISP): 238.0 ([37Cl M+H]+.), 236.1 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 301 using 3,5-dichloro-aniline instead of 4-fluoroaniline in step a).
The title compound, MS (ISP): 300.0 ([81Br M+H]+.), 298.1 ([79Br M+H]+.), was obtained analogous to the procedure described for Example 301 using 4-bromo-3-fluoro-aniline instead of 4-fluoroaniline in step a).
The title compound, MS (ISP): 238.1 ([M+H]+.), was obtained analogous to the procedure described for Example 301 using 3,5-difluoro-aniline instead of 4-fluoroaniline in step a).
The title compound, MS (ISP): 256.0 ([37Cl M+H]+.), 254.1 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 302 using 4-chloro-3-fluoro-aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 256.0 ([37Cl M+H]+.), 253.9 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 302 using 3-chloro-5-fluoro-aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 300.0 ([81Br M+H]+.), 298.1 ([79Br M+H]+.), was obtained analogous to the procedure described for Example 301 using 3-bromo-4-fluoro-aniline instead of 4-fluoroaniline in step a).
The title compound, MS (ISP): 282.0 ([M+H]+.), was obtained analogous to the procedure described for Example 302 using 2,2-difluoro-5-amino-benzodioxole instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 296.4 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 67 using 2,2-difluoro-5-aminobenzodioxole instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 256.1 ([37Cl M+H]+.), 253.9 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 302 using 3-chloro-4-fluoro-aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 285.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 2-amino-6-trifluoromethyl-pyridine instead of 4-trifluormethoxyaniline in step a).
The title compound, MS (ISP): 250.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3-aminobiphenyl instead of 2-methoxyaniline.
The title compound, MS (ISP): 318.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 4′-trifluoromethyl-biphenyl-3-ylamine instead of 2-methoxyaniline.
The title compound, MS (ISP): 284.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 3′-chloro-biphenyl-3-ylamine instead of 2-methoxyaniline.
The title compound, MS (ISP): 286.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 2-chloro-4-(trifluoromethyl)-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 286.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 4-chloro-2-(trifluoromethyl)-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 248.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 4-chloro-6-methoxy-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 294.2 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 4-chloro-6-phenyl-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 258.0 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using methylamine instead of ethylamine in step a) and 4-chloro-2-(trifluoromethyl)-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 268.2 ([37Cl M+H]+.), 266.1 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 302 using 3-chloro-4-methoxy-aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 242.1 ([37Cl M+H]+.), 240.1 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 186 using 4-chloro-3-fluoro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 268.2 ([37Cl M+H]+.), 266.2 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 302 using 4-chloro-3-methoxy-aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 290.1 (81Br 37Cl [M+H]+.), 288.1 (81Br 35Cl 79 Br37C [M+H]+.), 286.1 (79Br35Cl [M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 4-bromo-3-chloro-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 258.3 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 4-(trifluoromethoxy)-aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 294.0 (37Cl [M+H]+.), 292.1 (35Cl [M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-chloro-4-(trifluoromethyoxy)aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 272.1 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 4-(2,2,2-trifluoro-ethoxy)-phenylamine instead of 2-methoxyaniline.
The title compound, MS (ISP): 290.0 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 3-(1,1,2,2-tetrafluoroethoxy)aniline instead of 2-methoxyaniline.
The title compound, MS (ISP): 232.1 ([M+H]+.), was obtained analogous to the procedure described for Example 302 using 4-methoxy-aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 332.1 (81Br 37Cl [M+H]+.), 330.0 (81Br 35Cl/79Br 37Cl [M+H]+.), 328.1 (79Br35Cl [M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 67 using 4-bromo-3-chloro-aniline instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 286.1 ([M+H]+.), was obtained analogous to the procedure described for Example 302 using 4-trifluoromethoxy-aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 322.2 ([37Cl M+H]+.), 320.1 ([35Cl M+H]+.), was obtained analogous to the procedure described for Example 302 using 3-chloro-4-trifluoromethoxy-aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 314.0 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 67 using 4-(2,2,2-trifluoro-ethoxy)-phenylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): MS (ISP): 285.9 ([81Br M+H]+.), 283.9 ([79Br M+H]+.), was obtained analogous to the procedure described for Example 186 using 3-bromo-4-fluoro-aniline instead of m-anisidine in step a).
The title compound, MS (ISP): 318.0 ([M+H]+.), was obtained analogous to the procedure described for Example 302 using 3-(1,1,2,2-tetrafluoroethoxy)aniline instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 252.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using isopropylamine instead of ethylamine in step a) and 4,6-dichloropyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 220.4 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 67 using 3-amino-1-methylpyrazole instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 282.1 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 67 using 1-phenyl-1H-pyrazol-3-ylamine instead of 4-trifluoromethoxyaniline in step a).
The title compound, MS (ISP): 206.1 ([M+H]+.), was obtained analogous to the procedure described for Example 302 using 5-amino-1-methylpyrazole instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 268.3 ([M+H]+.), was obtained analogous to the procedure described for Example 302 using 1-phenyl-1H-pyrazol-3-ylamine instead of 4-bromoaniline in step a).
The title compound, MS (ISP): 249.1 ([M+H]+.), was obtained in comparable yield analogous to the procedure described for Example 63 using 4-(trifluoromethyl)-1,3-thiazol-2-amine instead of 2-methoxyaniline.
The title compound, MS (ISP): 288.1 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 229 using 2,2,2-trifluoroethylamine instead of ethylamine in step a) and sodium methoxide in 1,2-dimethoxyethane instead of sodium hydride/phenol in dimethylformamide in step b).
The title compound, MS (ISP): 326.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 210 using 2,2,2-trifluoroethylamine instead of ethylamine in step a) and 2-chloro-4-(trifluoromethyl)-pyrimidine instead of 2-chloro-4-methoxy-pyrimidine in step b).
The title compound, MS (ISP): 209.8; 211.8 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 63 using 2-amino-6-chloropyrazine instead of 2-methoxyaniline.
The title compound, MS (ISP): 252.3; 254.3 ((M+H)+.) was obtained in comparable yield analogous to the procedure described for Example 67 using 2-amino-6-chloropyrazine instead of 4-trifluormethoxyaniline in step a).
The ability of the compounds of the present invention to bind to TAAR1 was investigated in accordance with the test given hereinafter.
Materials and Methods
Construction of TAAR Expression Plasmids and Stably Transfected Cell Lines
For the construction of expression plasmids the coding sequences of human, rat and mouse TAAR 1 were amplified from genomic DNA essentially as described by Lindemann et al. (2005) Genomics 85, 372-385. The Expand High Fidelity PCR System (Roche Diagnostics) was used with 1.5 mM Mg2+ and purified PCR products were cloned into pCR2.1-TOPO cloning vector (Invitrogen) following the instructions of the manufacturer. PCR products were subcloned into the pIRESneo2 vector (BD Clontech, Palo Alto, Calif.), and expression vectors were sequence verified before introduction in cell lines.
HEK293 cells (ATCC # CRL-1573) were cultured essentially as described Lindemann et al. (2005) Genomics 85, 372-385. For the generation of stably transfected cell lines HEK293 cells were transfected with the pIRESneo2 expression plasmids containing the TAAR coding sequences (described above) with Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer, and 24 hours post transfection the culture medium was supplemented with 1 mg/ml G418 (Sigma, Buchs, Switzerland). After a culture period of about 10 days, clones were isolated, expanded and tested for responsiveness to trace amines (all compounds purchased from Sigma) with the cAMP Biotrak Enzyme immunoassay (EIA) System (Amersham) following the non-acetylation EIA procedure provided by the manufacturer. Monoclonal cell lines which displayed a stable EC50 for a culture period of 15 passages were used for all subsequent studies.
Membrane Preparation and Radioligand Binding
Cells at confluence were rinsed with ice-cold phosphate buffered saline without Ca2+ and Mg2+ containing 10 mM EDTA and pelleted by centrifugation at 1000 rpm for 5 min at 4° C. The pellet was then washed twice with ice-cold phosphate buffered saline and cell pellet was frozen immediately by immersion in liquid nitrogen and stored until use at −80° C. The cell pellet was then suspended in 20 ml HEPES-NaOH (20 mM), pH 7.4 containing 10 mM EDTA, and homogenized with a Polytron (PT 3000, Kinematica) at 10,000 rpm for 10 seconds. The homogenate was centrifuged at 48,000×g for 30 minutes at 4° C. and the pellet resuspended in 20 ml HEPES-NaOH (20 mM), pH 7.4 containing 0.1 mM EDTA (buffer A), and homogenized with a Polytron at 10,000 rpm for 10 seconds. The homogenate was then centrifuged at 48,000×g for 30 minutes at 4° C. and the pellet resuspended in 20 ml buffer A, and homogenized with a Polytron at 10,000 rpm for 10 seconds. Protein concentration was determined by the method of Pierce (Rockford, Ill.). The homogenate was then centrifuged at 48,000×g for 10 minutes at 4° C., resuspended in HEPES-NaOH (20 mM), pH 7.0 including MgCl2 (10 mM) and CaCl2 (2 ml) (buffer B) at 200 μg protein per ml and homogenized with a Polytron at 10,000 rpm for 10 seconds.
Binding assay was performed at 4° C. in a final volume of 1 ml, and with an incubation time of 30 minutes. The radioligand [3H]-rac-2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline was used at a concentration equal to the calculated Kd value of 60 nM to give a total binding at around 0.1% of the total added radioligand concentration, and a specific binding which represented approximately 70-80% of the total binding. Non-specific binding was defined as the amount of [3H]-rac-2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline bound in the presence of the appropriate unlabelled ligand (10 μM). Competing ligands were tested in a wide range of concentrations (10 pM-30 μM). The final dimethylsulphoxide concentration in the assay was 2%, and it did not affect radioligand binding. Each experiment was performed in duplicate. All incubations were terminated by rapid filtration through UniFilter-96 plates (Packard Instrument Company) and glass filter GF/C, pre-soaked for at least 2 h in polyethylenimine 0.3%, and using a Filtermate 96 Cell Harvester (Packard Instrument Company). The tubes and filters were then washed 3 times with 1 ml aliquots of cold buffer B. Filters were not dried and soaked in Ultima gold (45 D/well, Packard Instrument Company) and bound radioactivity was counted by a TopCount Microplate Scintillation Counter (Packard Instrument Company).
The preferred compounds show a Ki value (μM) in mouse on TAAR1 in the range of 0.0009-0.01 as shown in the table below.
| Number | Date | Country | Kind |
|---|---|---|---|
| 06122586 | Oct 2006 | EP | regional |
| Number | Name | Date | Kind |
|---|---|---|---|
| 2161938 | Sonn | Jun 1939 | A |
| 2457047 | Kyrides | Dec 1948 | A |
| 2731471 | Synerholm et al. | Jan 1956 | A |
| 2744909 | Speeter | May 1956 | A |
| 2744910 | Speeter | May 1956 | A |
| 2778836 | Morren | Jan 1957 | A |
| 2919274 | Faust et al. | Dec 1959 | A |
| 3161653 | Fruhstorfer et al. | Dec 1964 | A |
| 3354175 | Fruhstorfer et al. | Nov 1967 | A |
| 3377247 | Elbe | Apr 1968 | A |
| 3586695 | Wysong et al. | Jun 1971 | A |
| 3622579 | Stahle et al. | Nov 1971 | A |
| 3660423 | Wysong et al. | May 1972 | A |
| 3758476 | Rippel et al. | Sep 1973 | A |
| 3818035 | Binon et al. | Jun 1974 | A |
| 3818094 | Stahle et al. | Jun 1974 | A |
| 3992403 | Roebke | Nov 1976 | A |
| 4125620 | Stahle et al. | Nov 1978 | A |
| 4146647 | Lafon | Mar 1979 | A |
| 4323570 | Stenzel et al. | Apr 1982 | A |
| 4505918 | Huff et al. | Mar 1985 | A |
| 4517198 | Kurkela et al. | May 1985 | A |
| 4665095 | Winn et al. | May 1987 | A |
| 5464847 | Courtemanche et al. | Nov 1995 | A |
| 5610174 | Craig et al. | Mar 1997 | A |
| 5658938 | Geerts et al. | Aug 1997 | A |
| 7851626 | Ding et al. | Dec 2010 | B2 |
| 20020019390 | Wong et al. | Feb 2002 | A1 |
| 20030181354 | Abdulrazik | Sep 2003 | A1 |
| 20030236274 | Tasaka et al. | Dec 2003 | A1 |
| 20080096903 | Chen et al. | Apr 2008 | A1 |
| Number | Date | Country |
|---|---|---|
| 2246027 | Feb 2000 | CA |
| 0 024 829 | Mar 1981 | EP |
| 0 081 324 | Jun 1983 | EP |
| 0 125 410 | Nov 1984 | EP |
| 0 166 937 | Jan 1986 | EP |
| 0 331 374 | Sep 1989 | EP |
| 0 424 059 | Apr 1991 | EP |
| 0 576 350 | Dec 1993 | EP |
| 0 857 483 | Aug 1998 | EP |
| 0 924 209 | Jun 1999 | EP |
| 1 103 243 | May 2001 | EP |
| 1 413 576 | Apr 2004 | EP |
| 323 985 | Dec 1966 | ES |
| 6 551 | Dec 1968 | FR |
| 877306 | Sep 1961 | GB |
| 1016514 | Jan 1966 | GB |
| 63141969 | Dec 1986 | JP |
| WO 9622768 | Aug 1996 | WO |
| WO 9712874 | Apr 1997 | WO |
| 9731638 | Sep 1997 | WO |
| WO 9812183 | Mar 1998 | WO |
| WO 0130762 | May 2001 | WO |
| 0151472 | Jul 2001 | WO |
| WO 0181334 | Nov 2001 | WO |
| WO 0222801 | Mar 2002 | WO |
| WO 0240453 | May 2002 | WO |
| WO 02076950 | Oct 2002 | WO |
| WO 03092374 | Nov 2003 | WO |
| WO 2004014898 | Feb 2004 | WO |
| 2004018419 | Mar 2004 | WO |
| 2004022544 | Mar 2004 | WO |
| 2004022561 | Mar 2004 | WO |
| 2006119411 | Nov 2006 | WO |
| WO 2006119411 | Nov 2006 | WO |
| WO 2006133216 | Dec 2006 | WO |
| WO 2007024944 | Mar 2007 | WO |
| 2007084684 | Jul 2007 | WO |
| WO 2007085556 | Aug 2007 | WO |
| 2008046756 | Apr 2008 | WO |
| 2008046757 | Apr 2008 | WO |
| 2008046758 | Apr 2008 | WO |
| Entry |
|---|
| Hodson et al. Bioorganic & Medicinal Chemistry Letters 12 (2002) 3449-3452. |
| Altenbach et al., Synthesis and Structure-Activity Studies on N-[5-(1H-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidasole-Containing α1A-Adrenoceptor Agonist, J. Med. Chem. (2004), 47: 3220-3235. |
| Amemiya et al., Synthesis and α-Adrenergic Activities of 2-and 4-Substituted Imidazoline and Imidazoline Analogues, J. Med. Chem. (1992), 35:750-755. |
| Bagley et al., Synthesis and α2-Adrenegeric Activities of Imidazole and Imidazolidine Analogues: In Vitro and In Vivo Selectivity, Medicinal Chemistry Research (1994), 4:346-364. |
| Branchek et al., Trace amine receptors as targets for novel therapeutics: legend, myth and fact, Curr. Opin. Phamacol. (2003), 3:90-97. |
| Bunzow et al., Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor, Molecular Pharmacology (2001), 60: 1181-1188. |
| Carroll et al., In Vitro and In Vivo Characterization of Alpha-1A Selective Agonists and Their Utility for Stress Incontinence, Med. Chem. Res. (2004), 13:134-148. |
| De Bernardis et al., Conformationally Defined Adrenergic Agents. 3. Modifications to the Carbocyclic Ring of 5,6-Dihydroxy-1-(2-imidazolinyl)tetralin: Improved Separation of α1 and α2 Adrenergic Activities, J. Med. Chem. (1986), 29:1413-1417. |
| De Bernardis et al., Conformationally Defined Adregernic Agents. 5. Resolution, Absolute Configuration, and Pharmacological Characterization of the Enantiomers of 2-(5,6-Dihydroxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline: A Potent Agonist at α—Adrenoceptors, J. Med. Chem. (1987), 30:1011-1017. |
| Faust et al., Antihypertensive Agents: Derivatives of 2-Imidazoline and 1,4,5,6-Tetrahydropyrimidine, J. Org. Chem. (1961), 26: 4044-4047. |
| Hirashima et al., Three-Dimensional Common-Feature Hypotheses for Octopamine Agonist 2-(Arylimino)imidazolidines, Bioorganic & Medicinal Chemistry (2002), 10:117-123. |
| Holt, A., Imidazoline binding sites on receptors and enzymes:Emerging targets for novel antidepressant drugs?, Journal of Psychiatry & Neuroscience (2003), 28:409-414. |
| Jetter et al., Synthesis of 4-Substituted Imidazoles via Palladium-Catalyzed Cross-Coupling Reactions, Synthesis (1998), 829-831. |
| Law et al., Benzylimidazolines as h5-HT1B/1D Serotonin Receptor Ligands: A Structure-Affinity Investigation, J. Med. Chem. (1998), 41:2243-2251. |
| Lee et al., 4-[(N-Imidazol-2-ylmethyl)aniline]pyranopyridine Analogs as Novel Anti-Angiogenic Agents, Bull. Korean Chem. Soc. (2005), 25: 619-628. |
| Lindemann et al., A renaissance in trace amines inspired by a novel GPCR family, Trends in Pharmacol. Sci. (2005), 26:274-281. |
| Lindemann et al., Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors, Genomics (2005), 85: 372-385. |
| Matsunaga et al., C17,20 inhibitors. Part 2: Design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C17,20-lyase inhibitors, Bioorganic & Medicinal Chemistry (2004), 4314. |
| Matsunaga et al., Synthetic studies on (1S)-6,7-dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)2-methylpropan-1-ol as a selective C17,20-lyase inhibitor, Tetrahedron: Asymmetry (2004), 15: 2021-2028. |
| McCormack et al., Autoradiographic Localization of Tryptamine Binding Sites in the Rat and Dog Central Nervous System, J. Neurosci. (1986), 6:94-101. |
| McLennan, P;L., The Hypothermic Effect of Clonidine and Other Imidazolidines in Relation to their Ability to Enter the Central Nervous System in Mice, European Journal of Pharmacology (1981), 69:477-482. |
| Mosseau et al., A high-affinity [3H]tryptamine binding site in human brain, Prog. Brain Res. (1995), 106:285-291. |
| Nathanson, J.A.,Phenyliminoimidazolines: Characterization of a Class of Potent Agonists of Octopamine-Sensitive Adenylate Cylcase and Their Use in Understanding the Pharmacology of Octopamine Receptors, Amer. Soc. Pharmacology (1985), 28:254-268. |
| Ojida et al., Sterocontrolled synthesis of (1S)-1-(1H-imidazol-4-y1)-1-(6-methoxy-2-napthyl)-2-methylpropan-1-ol as a potent C17,20-lyase inhibitor,Tetrahedron: Asymmetry (2004), 15: 1555-1559. |
| Olmos et al., Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I1and I2 receptors, European Journal of Pharmacology (1994), 262: 41-48. |
| Prisinzano et al., 2-(aniline)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT-1D serotonin receptor ligands, Bioorganic & Medicinal Chemistry Letter (2004), 14:4697-4699. |
| Savola et al., Cardiovascular and Sedative α-Adrenoceptor Effects of Detomidine-like Arylalkyl Imidazoles and Associated Derivatives, Drug Res. (1988), 38:29-35. |
| Timmermans et al., Characterization of α-Adrenoceptor Populations. Quantitive Relationships between Cardiovascular Effects Initiated at Central and Peripheral α-Adrenoceptors, J. Med. Chem. (1981), 24:502-507. |
| Timmermans et al., Correlations between Central Hypotensive and Peripheral Hypertensive Effects of Structurally Dissimilar Alpha-Adrenoceptor Agonists, Life Sciences (1981), 28:653-660. |
| Turner et al., A Facile Route to Imidazol-4-yl Anions and Their Reaction with Carbonyl Compounds, J. Org. Chem. (1991), 56: 5739-5740. |
| Usdin, E. and M. Sandler, Eds., Psychopharmacology Series, vol. 1: Trace Amines and the Brain (1976), 1-281. |
| Wentland et al., Syntehsis and Antidepressant Properties of Novel 2-Substituted 4,5-Dihydro-1H-imidazole Derivatives, J. Med. Chem. (1987), 30:1482-1489. |
| Zhang et al., Medetomidine Analogs as α2-Adrenegeric Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with α2-Adrenoceptors Involving a “Methyl Pocket”, J. Med. Chem. (1997), 40: 3014-3024. |
| Hodson, S.J., et al., Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 3449-3452 (2002) XP002307084. |
| Swett; Yellin, J. Med. Chem., vol. 13, No. 5, pp. 968-970 (1970) XP002464069. |
| Glenn, et al., J. Med. Chem., vol. 49, No. 19, pp. 5710-5727 (2006) XP002464070. |
| Chilean Office Action in Corresponding Appl. 2971-07 dated Oct. 18, 2010. |
| (English Translation of Jap Office Action in Corres Appl 817166 Dec. 6, 2011). |
| (Translation Russian Office Action in Appl. No. 2009112496 Aug. 26, 2011). |
| (Translation of Korean Off Act for Corr App KR20020084091 Oct. 27, 2011). |
| (Peruvian Office Action in Corres. PE Appl. 1403Jan Jan. 6, 2012). |
| Farmacia de Remington (17th Edition),:2181-2184 ( 1987). |
| Number | Date | Country | |
|---|---|---|---|
| 20080119535 A1 | May 2008 | US |
